CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Peginterferon Lambda-1AWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)


Name (Synonyms) Correlation
drug1031 systemic treatment Wiki 1.00

Correlated MeSH Terms (2)


Name (Synonyms) Correlation
D011014 Pneumonia NIH 0.08
D018352 Coronavirus Infections NIH 0.06

Correlated HPO Terms (1)


Name (Synonyms) Correlation
HP:0002090 Pneumonia HPO 0.15

There is one clinical trial.

Clinical Trials


1 Interferon Lambda for Immediate Antiviral Therapy at Diagnosis (ILIAD): A Phase II Randomized, Open-label, Multicenter, Trial to Evaluate the Effect of Peginterferon Lambda for the Treatment of COVID-19

Interferon lambda is one of the main arms of the innate antiviral immune response and is critical for controlling respiratory viral infections in mice. Interferon lambda has a better side effect profile than other interferons because of the limited tissue distribution of its receptor. Peginterferon lambda is a long-acting form that has been studied extensively in human trials in viral hepatitis, confirming its safety. We propose to evaluate peginterferon-lambda in ambulatory and hospitalized patients with mild to moderate COVID-19.

NCT04354259 Sars-CoV2 Drug: Peginterferon Lambda-1A

Primary Outcomes

Description: The proportion of participants with negative SARS-CoV-2 RNA on nasopharyngeal swab.

Measure: Cohort A (Ambulatory) - Primary Efficacy Endpoint

Time: At day 8

Description: Rate of combined treatment-emergent and treatment-related severe adverse events (SAEs).

Measure: Cohort A (Ambulatory) - Primary Safety Endpoint

Time: Day 1 to Day 15

Description: The proportion of participants with negative SARS-CoV-2 RNA on nasopharyngeal swab.

Measure: Cohort B (Hospitalized) - Primary Efficacy Endpoint

Time: At Day 15

Description: Rate of combined treatment-emergent and treatment-related severe adverse events (SAEs).

Measure: Cohort B (Hospitalized) - Primary Safety Endpoint

Time: Day 1 to Day 30

Secondary Outcomes

Description: Time to resolution of all symptoms (fever, cough, diarrhea)

Measure: Cohort A (Ambulatory) - Clinical Outcome #1

Time: Day 1 to Day 15

Description: Change in respiratory symptom score.

Measure: Cohort A (Ambulatory) - Clinical Outcome #2

Time: Day 1 to Day 8

Description: Change in gastrointestinal symptom score.

Measure: Cohort A (Ambulatory) - Clinical Outcome #3

Time: Day 1 to Day 8

Description: Change in fever symptom score.

Measure: Cohort A (Ambulatory) - Clinical Outcome #4

Time: Day 1 to Day 8

Description: Need for hospital admission.

Measure: Cohort A (Ambulatory) - Clinical Outcome #5

Time: Day 1 to Day 15

Description: Adverse events.

Measure: Cohort A (Ambulatory) - Clinical Outcome #6

Time: Day 1 to Day 15

Description: Serious adverse events.

Measure: Cohort A (Ambulatory) - Clinical Outcome #7

Time: Day 1 to Day 15

Description: Proportion negative for SARS-CoV-2 RNA by nasopharyngeal swab

Measure: Cohort A (Ambulatory) - Virologic/Immunological Outcome #1

Time: At Day 4

Description: Time to SARS-CoV-2 RNA negativity on mid-turbinate nasal swab

Measure: Cohort A (Ambulatory) - Virologic/Immunological Outcome #2

Time: Day 1 to Day 15

Description: Proportion with SARS-CoV-2 RNA in blood and saliva.

Measure: Cohort A (Ambulatory) - Virologic/Immunological Outcome #3

Time: Day 1 and Day 8

Description: Proportion with SARS-CoV-2 antibodies blood and saliva.

Measure: Cohort A (Ambulatory) - Virologic/Immunological Outcome #4

Time: Day 1 and Day 8

Description: Proportion negative for SARS-CoV-2 RNA by nasopharyngeal swab by interferon lambda 4 (IFNL4) genotype

Measure: Cohort A (Ambulatory) - Virologic/Immunological Outcome #5

Time: Through day 8

Description: Change in laboratory and inflammatory markers (hemoglobin, white blood cell count, lymphocyte count, ferritin, lactate dehydrogenase, c-reactive protein, D-dimers, troponin).

Measure: Cohort A (Ambulatory) - Virologic/Immunological Outcome #6

Time: Day 1 to Day 8

Description: Proportion with symptom development among household contacts

Measure: Cohort A (Ambulatory) - Transmission Outcome #1

Time: Day 1 to Day 15

Description: Proportion with confirmed diagnosis of COVID-19 among household contacts.

Measure: Cohort A (Ambulatory) - Transmission Outcome #2

Time: Day 1 to Day 30

Description: ICU admission during hospitalization

Measure: Cohort B (Hospitalized) - Clinical Outcome #1

Time: Day 1 to day 30

Description: Need for intubation

Measure: Cohort B (Hospitalized) - Clinical Outcome #2

Time: Day 1 to Day 15

Description: Length of hospital stay

Measure: Cohort B (Hospitalized) - Clinical Outcome #3

Time: Day 1 to Day 15

Description: Change in respiratory symptom score

Measure: Cohort B (Hospitalized) - Clinical Outcome #4

Time: Day 0 to 8 and Day 0 to 15

Description: Readmission to hospital

Measure: Cohort B (Hospitalized) - Clinical Outcome #5

Time: By day 30 and Day 90

Description: All-cause mortality

Measure: Cohort B (Hospitalized) - Clinical Outcome #6

Time: At day 30 and day 90

Description: COVID-19-related mortality

Measure: Cohort B (Hospitalized) - Clinical Outcome #7

Time: At day 30

Description: Resolution of CXR findings

Measure: Cohort B (Hospitalized) - Clinical Outcome #8

Time: At Day 15

Description: Adverse (AEs)

Measure: Cohort B (Hospitalized) - Clinical Outcome #9

Time: By day 30

Description: Serious Adverse Events (SAEs)

Measure: Cohort B (Hospitalized) - Clinical Outcome #10

Time: By day 30

Description: Frequency of dose reduction or dose omission for the second dose of peginterferon lambda

Measure: Cohort B (Hospitalized) - Clinical Outcome #11

Time: Day 8 to day 12

Description: Proportion negative for SARS-CoV-2 RNA by NP swab.

Measure: Cohort B (Hospitalized) - Virologic/Immunological Outcome #1

Time: Day 8

Description: Time to SARS-CoV-2 RNA negativity by nasopharyngeal swab

Measure: Cohort B (Hospitalized) - Virologic/Immunological Outcome #2

Time: Day 1 to Day 15

Description: Correlation of clinical and virologic response with interferon lambda 4 (IFNL4) genotype

Measure: Cohort B (Hospitalized) - Virologic/Immunological Outcome #3

Time: Through Day 15

Description: Change in laboratory and inflammatory markers (hemoglobin, white blood cell count, lymphocyte count, ferritin, lactate dehydrogenase, c-reactive protein, D-dimers, troponin)

Measure: Cohort B (Hospitalized) - Virologic/Immunological Outcome #4

Time: From day 0 to day 8 and to day 15

Description: Time to SARS-CoV-2 RNA negativity by rectal swab

Measure: Cohort B (Hospitalized) - Virologic/Immunological Outcome #5

Time: Day 0 to Day 8

Description: Proportion with SARS-CoV-2 Antibody.

Measure: Cohort B (Hospitalized) - Virologic/Immunological Outcome #6

Time: At Day 8 and Day 15

Description: Proportion with SARS-CoV-2 RNA in blood and saliva.

Measure: Cohort B (Hospitalized) - Virologic/Immunological Outcome #7

Time: Day 0, Day 8, and Day 15


No related HPO nodes (Using clinical trials)